ROCKVILLE, Md. & LONDON----Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ in seropositive patients with systemic lupus erythematosus .